GlassScriptPhysician profile
Howard D Klein
NPI 1285717033
$5,213.28
in general payments reported to CMS, 2019-2025
33 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $342 · 2021: $204 · 2022: $728 · 2023: $1,484 · 2024: $1,051 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223 · Education: $33.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,223.24 |
| Education | $33.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.95 | 2019-2025 | |
| Janssen Biotech, INC. | $1,069.05 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $573.12 | 2019-2025 | Gattex, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.26 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $293.81 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $191.15 | 2024-2025 | Voquezna |
| Celgene Corporation | $187.17 | 2022-2024 | Zeposia |
| Pfizer INC. | $121.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $113.31 | 2019-2023 | Dificid |
| Celltrion USA INC. | $107.45 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $89.72 | 2019-2023 | Linzess |
| Madrigal Pharmaceuticals | $62.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $58.76 | 2022-2023 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $49.24 | 2025 | |
| Fresenius Kabi USA, LLC | $47.86 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $47.74 | 2022-2025 | Rebyota |
| Lilly USA, LLC | $46.72 | 2023 | |
| Aimmune Therapeutics, INC. | $46.16 | 2025 | Zenpep |
| Genzyme Corporation | $40.08 | 2025 | |
| Amgen INC. | $29.81 | 2020 | |
| Apollo Endosurgery US INC | $26.13 | 2020 | |
| Stryker Corporation | $23.73 | 2025 | Neptune, Pedi-Pom |
| Exact Sciences Corporation | $23.23 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $20.86 | 2024 | Ibsrela |
| Braintree Laboratories, INC. | $20.22 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.71 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $19.68 | 2019 | |
| Axonics, INC. | $18.76 | 2023 | Axonics |
| Intercept Pharmaceuticals, INC. | $18.27 | 2022 | |
| Redhill Biopharma INC. | $17.50 | 2023 | Talicia, Aemcolo |
| Shire North American Group INC | $14.98 | 2019 | |
| Alfasigma USA, INC. | $13.44 | 2020 | |
| Daiichi Sankyo INC. | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.